Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2021; 12(7): 932-938
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.932
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.932
Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor
Jelena Marinkovic-Radosevic, Department of Endocrinology, Diabetes and Metabolism, Sisters of Charity Clinical Hospital Centre, Zagreb 10000, Croatia
Maja Cigrovski Berkovic, Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, Clinical Hospital Dubrava, Zagreb 10000, Croatia
Maja Cigrovski Berkovic, Department of Kinesiological Anthropology and Methodology, Faculty of Kinesiology, University of Zagreb, Zagreb 10000, Croatia
Egon Kruezi, Department of Gynecology and Obstetrics, Sisters of Charity Clinical Hospital Centre, Zagreb 10000, Croatia
Ines Bilic-Curcic, Department of Pharmacology, Faculty of Medicine, University of J. J. Strossmayer Osijek, Osijek 31000, Croatia
Ines Bilic-Curcic, Clinical Hospital Center Osijek, Osijek 31000, Croatia
Anna Mrzljak, School of Medicine, University of Zagreb, Zagreb 10000, Croatia
Anna Mrzljak, Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Zagreb 10000, Croatia
Author contributions: Marinkovic-Radosevic J and Cigrovski Berkovic M made contributions to the conception and design of the study, drafted, and revised the manuscript critically; Kruezi E, Bilic-Curcic I, and Mrzljak A collected data, drafted and wrote the manuscript; All authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maja Cigrovski Berkovic, MD, Assistant Professor, Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, Clinical Hospital Dubrava, Ulica Gojka Šuška 6, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com
Received: March 13, 2021
Peer-review started: March 13, 2021
First decision: March 30, 2021
Revised: March 30, 2021
Accepted: June 22, 2021
Article in press: June 22, 2021
Published online: July 15, 2021
Peer-review started: March 13, 2021
First decision: March 30, 2021
Revised: March 30, 2021
Accepted: June 22, 2021
Article in press: June 22, 2021
Published online: July 15, 2021
Core Tip
Core Tip: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a new class of antidiabetic agents with beneficial cardiovascular, bodyweight, and antihyperglycemic effects. Although not approved for the treatment of polycystic ovary syndrome (PCOS), they might be an attractive therapeutic addition for the related metabolic, reproductive, and psychological consequences. Recent studies with SGLT-2 inhibitors in PCOS patients showed promising improvements in anthropometric parameters and body composition. Thus, it is important to explore the SGLT-2 inhibitors potential as an early therapeutic option in PCOS due to its high cardiometabolic risk.